TORONTO, Jan. 11 /CNW/ - Theralase(TM) Technologies Inc. (TSX-V: TLT &
OTC BB: TLTFF) ("Theralase"), a designer, manufacturer and distributor of
therapeutic medical laser systems, announced today that, effective
December 21, 2007, its Board of Directors appointed PricewaterhouseCoopers
LLP, Chartered Accountants ("Pricewaterhouse") as the Company's new
independent auditors, replacing the firm of Collins Barrow, Chartered
Accountants ("Collins Barrow").
The decision to change auditors was not the result of any disagreement
between the Company and Collins Barrow on any matter of accounting principals
or practices, financial statement disclosure, or auditing scope or procedure.
Theralase shareholders will be asked to approve the appointment of
Pricewaterhouse at the next annual meeting of shareholders.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and distributes
patented, super-pulsed laser technology used in a wide range of
bio-stimulation and bio-destruction clinical applications. The Theralase
technology platform targets several diverse healthcare sectors - firstly, for
non-invasive pain management and clinical therapy, in hundreds of neural
muscular skeletal conditions, (including arthritis) - secondly, to
bio-stimulate and accelerate wound care and healing, (including; bone fracture
regeneration and osteoarthritic conditions) - and thirdly, combining
photodynamic compounds with super-pulsed, biofeedback laser technology to
attack specifically targeted cancers, bacterium, viruses and fat cells.
For a complete profile of Theralase Technologies Inc. and its products
visit the corporate website, www.theralase.com, and the regulatory website at
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the contents of this
For further information:
For further information: Roger Dumoulin-White, Theralase Technologies
Inc., President & CEO, (416) 447-8455, email@example.com; Vanessa
Beresford, The Equicom Group Inc., (416) 815 0700, ext 227,